Chronic Hepatitis Therapeutics Market
Number of pages: 100 | Report Format: PDF | Published date: November 14, 2022
Historical Years – 2023 | Base Year – 2023 | Forecasted Years – 2024-2032
|
Report Attribute |
Details |
|
Market size value in 2024 |
US$ 14.05 billion |
|
Revenue forecast in 2032 |
US$ 38.96 billion |
|
Growth Rate |
CAGR of 12% from 2024 to 2032 |
|
Base year for estimation |
2023 |
|
Forecast period |
2024-2032 |
|
Segments covered |
Drug Class, Distribution channel, and Region. |
|
Regional scope |
North America, Europe, Asia Pacific, and the Rest of the World (ROW) |
The global chronic hepatitis therapeutics market was valued at US$ 14.05 billion in 2023 and is expected to register a revenue CAGR of 12.00% to reach US$ 38.96 billion by 2032.
Market Fundamental
Hepatitis C is a viral infection of the liver. It can result in both acute and chronic illnesses. It has the potential to cause death. Hepatitis C is transmitted through contact with infected blood. Sharing needles or syringes, as well as unsafe medical procedures like blood transfusions with unscreened blood products, can all lead to this. Chronic hepatitis C is the term for the hepatitis C virus infection that lasts for a long time. Until the virus injures the liver to the point that it results in the signs and symptoms of liver disease, chronic hepatitis C is typically a "silent" infection for many years. The hepatitis C virus is responsible for 60 to 70% of cases of chronic hepatitis, with at least 75% of acute hepatitis C cases progressing to chronic disease. In adults, 5 to 10% of hepatitis B cases develop into chronic disease, sometimes with hepatitis D coinfection. Acute hepatitis B can become chronic in up to 90% of infected newborns and 25-50% of young children.
The Hepatitis E virus causes chronic hepatitis in people with weakened immune systems, such as those taking immunosuppressive drugs after an organ transplant, cancer patients, or HIV patients. Because acute hepatitis C rarely causes symptoms, it frequently gets misdiagnosed. Jaundice is one of the possible indications and symptoms, along with fatigue, nausea, fever, and muscle aches. Acute symptoms start to show one to three months after virus exposure and last for two to three months. Furthermore, there are exceptions to the rule of chronic hepatitis C infection. After the acute period, some patients spontaneously clear HCV from their bodies, a phenomenon known as viral clearance. Rates of spontaneous viral clearance in investigations of individuals with acute HCV infection have ranged from 15% to 25%. Antiviral treatment is also effective in treating acute hepatitis C.
[6384324]
Market Dynamics
The market size for hepatitis C diagnosis and treatment is expected to grow because of factors like the disease's high prevalence and growing public awareness. An estimated 71 million people worldwide have chronic hepatitis C virus infection, according to a World Health Organization (WHO) report published in March 2020. The market share for hepatitis C diagnosis and treatment is also driven by the participation of numerous companies in developing therapies and medications. The market is experiencing growth due to government support and pharmaceutical subsidies in various countries. The rise of clinical research and growing interest in antiviral drugs for the illness is also propelling the overall market.
Additionally, government policies to improve healthcare infrastructure, increase funding, introduce innovative targeted therapeutic approaches like vaccinations, and increase healthcare spending all positively affect the market value and thus help the market growth. Major players in the field invest money in research and development (R&D) initiatives to generate cutting-edge innovations. They also merge, acquire, and form joint ventures and alliances to expand their operations. Collectively, these factors help accelerate the growth of the hepatitis treatment industry. The market for hepatitis treatments is expected to expand because of favorable reimbursement policies implemented by government bodies in several countries. Breakthroughs in medical technologies or alternative therapeutic approaches, such as gene therapy, RNA-based therapies, or immunotherapy targeting chronic hepatitis, can potentially provide more effective and targeted treatments than traditional pharmaceuticals.
Market Ecosystem
The global chronic therapeutic market has been analyzed from three perspectives: by drug class, distribution channel, and region.
Chronic Hepatitis Therapeutics Market by Drug Class
[2132443]
Based on drug class, the global chronic hepatitis therapeutics market has been segmented into interferon alphas, NS5a inhibitors, nucleoside/nucleotide analogs, thrombopoiesis stimulating agents, and others.
Interferon alphas have potent antiviral activity. They inhibit the replication of the hepatitis B and C viruses, aiding in the control of the virus's spread throughout the body. This antiviral effect is critical for lowering viral loads and slowing the progression of chronic hepatitis. Interferon alphas are sometimes used in conjunction with other antiviral medications or treatments. This combined approach can improve treatment efficacy, particularly in cases where the virus is resistant to one type of treatment alone. Combination therapies can improve the overall outcome of chronic hepatitis treatment. Interferon alphas can help prevent or delay the progression of chronic hepatitis complications like cirrhosis and liver cancer. Interferon alphas help to manage the disease over time and improve patient outcomes by targeting the underlying viral infection.
The interferons alphas account for a notable revenue share in the global market. Alpha interferon is a cytokine the innate immune system produces in response to environmental stimuli, including viral infections. Alpha interferon has been developed in various formulations to treat a variety of cancers and viral infections; its primary use has still been for chronic hepatitis C.
Chronic Hepatitis Therapeutics Market by Distribution Channel
Based on drug class, the global chronic hepatitis therapeutics market has been segmented into hospital, retail, and online pharmacies.
The hospital pharmacies segment accounted for a maximum revenue share, owing to the distribution of pharmaceuticals at these facilities ensuring a greater level of safety and guidance regarding the administration of therapies. Sometimes, hospital pharmacies may be involved in compounding or preparing specialized formulations of medications based on individual patient needs. They oversee keeping an inventory of medications, ensuring proper storage, and managing stock levels to avoid shortages. Hospital pharmacists frequently work closely with other healthcare providers to optimize medication regimens, monitor patient responses, and address adverse reactions. Hospital pharmacies provide inpatients with immediate access to medications, ensuring timely treatments. Hospitals' proximity to other healthcare departments allows for more integrated patient care and communication between pharmacists and healthcare teams.
Furthermore, the retail pharmacy segment is projected to hold the second-most dominant share since these organizations may offer effective services regarding prescription refills. Retail pharmacies, including community pharmacies and chain drugstores, are important channels for distributing chronic hepatitis medications. Patients can fill their prescriptions and access necessary therapies at these retail outlets.
Likewise, a greater CAGR is anticipated for online pharmacies because of how comfortable and simple it is to use these services to buy medications.
Chronic Hepatitis Therapeutics Market by Region
Based on region, the chronic hepatitis therapeutics market is segmented into North America, Europe, Asia Pacific, and the Rest of the World.
North America was the region that generated the most revenue, which is also expected to take the lead in the global market over the forecast period. The hepatitis therapeutics market in the United States is expected to grow due to rising hepatitis incidence and mortality rates, as well as increased spending on hepatitis medications. The United States is an important market because of its high demand, relatively wealthy patient population, and familiarity with cutting-edge treatments. The most important factors contributing to the high share are sophisticated healthcare infrastructure, reimbursement availability, and access to the most advanced and innovative treatments. Several factors contribute to the growth of the US market, including significant industry competitors, the expansion of regional awareness programs, and the introduction of cutting-edge goods.
In developing nations like China, India, and other Southeast Asian nations, there is a sizable patient pool who has hepatitis C. However, the patient population depends on the individual governments for the subsidized pharmaceuticals. While the contribution to revenue is lower, the market is expanding at a faster CAGR due to an elevated level of demand.
Similarly, Europe is anticipated to account for the second-largest global market share due to growing hepatitis C awareness and the increase in the patient population. As of the historic projection period, 14 million people in Europe have hepatitis C, according to the WHO.
Additionally, Asia-Pacific is expected to be the fastest-growing regional market due to its enormous patient population suffering from hepatitis C and the growing number of government and private institutes endeavors to create awareness about hepatitis C.
Competitive Landscape
The prominent players operating in the global chronic hepatitis therapeutics market are:
Strategic Development
North America is the key growth region in the global chronic hepatitis therapeutics market.
The rising product launches and increasing research and development activities are the prime driving factors of the market.
The interferons alphas dominated the market during forecast period.
The global chronic hepatitis therapeutics market is expected to witness a CAGR of 12% during the forecast period.
Some of the prominent market players in the global chronic hepatitis therapeutics market include Genentech, Inc., Bluejay Therapeutics Inc., GSK plc., Gilead Sciences, Inc. and others.
Table of Content
*Insights on financial performance are subject to the availability of information in the public domain
List of Tables
List of Figures